Key result
Adding metformin to heart failure therapy boosts EF by ~6% and lowers NT-proBNP in non-diabetics.
Why the study?
Heart failure remains a difficult challenge requiring promoting interventions, and metformin has emerged as a promising therapy.
Does adding daily metformin to standard treatment improve cardiac parameters and biomarkers in non-diabetic patients with heart failure and mid-range ejection fraction?
RCT (n=60)
Randomized
Does adding daily metformin to standard treatment improve cardiac parameters and biomarkers in non-diabetic patients with heart failure and mid-range ejection fraction?
Adding low-dose metformin to standard therapy in non-diabetic patients with heart failure and mid-range ejection fraction significantly improves ejection fraction and reduces NT-proBNP over 3 months.
Answers are grounded in this paper and cite their sources.
Supports metformin addition in non-diabetic HFmrEF; extends evidence from diabetic populations to this group.
Heart failure (HF) remains a difficult challenge to the healthcare system, necessitating promoting interventions and multidrug management. Metformin, typically used to manage diabetes, has emerged as a promising intervention in the treatment of HF. This study aimed to assess the effect of adding metformin to the standard treatment of HF on cardiac parameters. This clinical study comprised 60 newly diagnosed HF patients randomly assigned to two groups: Group C received standard HF treatment, while Group M received standard HF treatment in addition to daily metformin (500 mg). After 3 months of treatment, group M showed a significantly higher ejection fraction (EF) compared to Group C (6.1% and 3.2%, respectively; p-value=0.023) and a reduction in the left ventricular end-diastolic pressure (LVEDD) (0.28, and 0.21 mm respectively; p-value=0.029). No significant differences were observed in the interventricular septal thickness (IVST) or left ventricular end-systolic pressure (LVESD). For cardiac markers, N-Terminal pro-BNP (NT-proBNP) showed the highest reduction in Group M compared to Group C (719.9 pg/ml and 271.9 pg/ml respectively; p-value=0.009). No significant changes were reported for soluble ST2. Metformin demonstrated cardiac protective effects by increasing EF and reducing NT-proBNP. Given its affordability and accessibility, metformin offers a valuable addition to the current HF treatment options. This positive effect may be attributed to mechanisms that enhance the impact of conventional HF treatments or vice versa.
No takes yet. Share an insight, caveat, or question.
Fawzi et al. (2023) conducted an RCT in Heart failure with mid-range ejection fraction (n=60). Metformin vs. Standard HF treatment was evaluated on Ejection fraction (EF) (p=0.023). Adding daily metformin to standard heart failure treatment increased ejection fraction and reduced NT-proBNP at 3 months in non-diabetic patients.
Synapse has enriched 10 related papers. Consider them for comparative context: